tbuckley/cabot-search huggingface dataset:
Abstract 14944: Factor Xa Aggravates Atherosclerosis by Promoting Inflammasome Formation Through Suppressing Autophagy
Authors: Yusuke Ito, Yasuhiro Maejima, Natsuko Tamura, Ryo Watanabe, Mitsuaki Isobe
Journal: Circulation (2015)

Introduction: Growing body of evidence suggests that factor Xa (FXa), an endogenous coagulation factor, plays a critical role in promoting atherosclerosis. However, the mechanism how FXa facilitates atherogenesis remains unclear. Hypothesis: FXa promotes progression of atherosclerosis through protease-activated receptor-2 (PAR-2)-mediated modulation of autophagy machinery and innate inflammatory response. Methods and Results: Administration of 12 mg/kg/day of rivaroxaban (Riv), a direct FXa inhibitor, to the mice effectively elongated prothrombin time (Riv 12mg/kg/day: 14.6 ± 0.6*, Riv 6mg/kg/day: 9.2 ± 0.2*, Untreated: 7.1 ± 0.1 sec, * P &lt; 0.05) and markedly suppressed plasma FXa activity (Riv 12mg/kg/day: 1.9 ± 0.1*, Riv 6mg/kg/day: 2.6 ± 0.3*, Untreated: 3.9 ± 0.3 RFU, * P &lt; 0.05) compared with the mice treated with lower dose of Riv (6 mg/kg/day) or untreated mice. Riv treatment to ApoE -/- mice fed with a high-fat diet for 20 weeks markedly reduced the atherosclerotic areas in the sinus and whole aorta to 42.5 % ( P &gt; 0.05) and 50.4 % ( P &gt; 0.05), respectively. Moreover, Riv also reduced the inflammasome formation in the atherosclerotic lesions as evaluated by immunostaining of NLRP3. In vitro experiments using RAW264.7, a murine macrophage cell line, or mouse peritoneal macrophages demonstrated that treatment of 7-ketocholesterol (7KC), an atherosclerotic lesional oxysterol that promotes inflammation through inflammasome formation, significantly activated autophagy as evidenced by the increase in LC3-II protein and the number of autophagosomes. Treatment with FXa (50 nM) markedly induced phosphorylation of mTOR (Ser 2448 ) and suppressed 7KC-induced autophagy, which was reversed in the presence of Riv (1 μM). In addition, Treatment with FXa significantly enhanced inflammasome formation induced by 7KC, which was blocked in the presence of Riv, as evaluated by the amount of NLRP3, caspase-1, and IL-1β. Importantly, however, treatment with FXa failed to block 7KC-induced autophagy and inflammasome activation in macrophages derived from PAR-2 -/- mice. Conclusion: FXa positively regulates the atherogenesis, possibly through PAR-2-mediated pathway by inhibiting autophagy which, in turn, promoting inflammasome activation in macrophages.
Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study
Authors: Solomon A. Graf, Ryan D. Cassaday, Karolyn K. Morris, Heather A. Rasmussen, Pamela S. Becker, Thomas R. Chauncey, Sandra Kanan, Lorinda A. Soma, Stephen D. Smith, Ajay K. Gopal
Journal: Blood (2018)
Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®
Authors: Jeffrey A Gilreath, Tsewang Tashi, Soo Jin Kim, Kimberly Hickman, Josef T. Prchal
Journal: Blood (2018)
Image Gallery: Generalized cutaneous Rosai–Dorfman disease presenting as acneiform lesions
Authors: Y. Zhang, H. Chen
Journal: British Journal of Dermatology (2019)

Funding sources: CAMS Innovation Fund for Medical Sciences (CIFMS‐2017‐I2M‐1‐017) and Peking Union Medical College Youth Fund (3332017168). Conflicts of interest: none to declare. Dear Editor, A 48‐year‐old man presented with a 4‐month history of asymptomatic, dome‐shaped, red‐brown, shiny surfaced papules and nodules on his face, limbs and trunk (a and b). Imaging, clinical examination and laboratory findings were unremarkable. Histopathology demonstrated numerous infiltrating histiocyte‐engulfed inflammatory cells, forming 'emperipolesis' (indicated, c). Immunohistochemically, histiocytes were CD68 and S100 positive, but CD1a negative. Cutaneous Rosai–Dorfman disease (CRDD) was diagnosed. CRDD is a rare entity, especially presenting as generalized acneiform lesions. The shiny surface and absence of pustules may be a useful clinical clue to distinguish CRDD from acne, and the histological and immunohistochemical features play a decisive role in diagnosis.
Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies
Authors: Fabricio Espinosa-Ortega, Marie Holmqvist, Helene Alexanderson, Helena Storfors, Tsuneyo Mimori, Ingrid E Lundberg, Johan Rönnelid
Journal: Annals of the Rheumatic Diseases (2019)

More than 15 autoantibodies have been identified in patients with idiopathic inflammatory myopathies (IIM). Most of them are specific to patients with IIM and therefore called myositis-specific autoantibodies (MSA).1 There is no standardised approach of MSA testing to be used in clinical settings. Immunoprecipitation (IP) of RNA and/or proteins in cellular lysates has traditionally been considered the golden standard for most autoantibodies but does not differentiate between antibodies targeting proteins with the same molecular weight and is not routinely available. Line blot assays (LB) represent a faster and semi-quantitative option to detect autoantibodies.2 3 Our aim was to compare a LB version with 16 specificities and an IP-based algorithm, as well as to describe clinical associations to autoantibody specificities in a cohort of patients classified as IIM.

The first available sera collected between 2013 and 2017, from 110 patients classified as having IIM4 followed at the rheumatology clinic at Karolinska University Hospital (Stockholm, Sweden) and sera from 60 healthy controls were included. We used a commercial LB assay (Euroline Myositis …
Abstract 15241: Prediction of Incident Adverse Cardiovascular Disease Events Using Left Ventricular Mass: Impact of Adding Trabecular and Papillary-Muscle Mass to Conventional (Compacted) Mass
Authors: Saadia Qazi, Philimon N Gona, Carol J Salton, Martin G Larson, Christopher J O’Donnell, Warren J Manning, Michael L Chuang
Journal: Circulation (2016)

Background: Left ventricular mass (LVM) by volumetric cardiovascular magnetic resonance (CMR) is an independent predictor of incident adverse cardiovascular disease (CVD) events. Prior studies have used compacted LVM (cLVM), ignoring trabecular and papillary-muscle mass (TPM). We assessed whether use of total LVM (TotLVM), the sum of cLVM and TPM, augments prediction of incident adverse CVD events over a cLVM-based model. Methods: A total of 1494 Framingham Offspring cohort members (65±9y, 46.8% men) underwent ECG-gated, contiguous multislice LV short-axis bSSFP CMR during 2002-2006 and had cLVM and TotLVM determined. cLVM was calculated from manually traced endo- and epicardial borders. TPM was quantified by custom software using thresholds based on signal intensities of cLVM and the LV bloodpool. Both cLVM and TotLVM were indexed (i) to body surface area. Adverse CVD events comprised CVD death, myocardial infarction, unstable angina, ischemic stroke, and first admission for heart failure. Seventy Offspr...
A Motor Theory of Sleep-Wake Control: Arousal-Action Circuit
Authors: Danqian Liu, Yang Dan
Journal: Annual Review of Neuroscience (2019)

Wakefulness, rapid eye movement (REM) sleep, and non-rapid eye movement (NREM) sleep are characterized by distinct electroencephalogram (EEG), electromyogram (EMG), and autonomic profiles. The circuit mechanism coordinating these changes during sleep-wake transitions remains poorly understood. The past few years have witnessed rapid progress in the identification of REM and NREM sleep neurons, which constitute highly distributed networks spanning the forebrain, midbrain, and hindbrain. Here we propose an arousal-action circuit for sleep-wake control in which wakefulness is supported by separate arousal and action neurons, while REM and NREM sleep neurons are part of the central somatic and autonomic motor circuits. This model is well supported by the currently known sleep and wake neurons. It can also account for the EEG, EMG, and autonomic profiles of wake, REM, and NREM states and several key features of their transitions. The intimate association between the sleep and autonomic/somatic motor control circuits suggests that a primary function of sleep is to suppress motor activity.
Abstract A022: Role of metallothionein in the pathogenesis of prostate cancer
Authors: Sobia Hamid, Mariam Anees
Journal: Cancer Research (2018)

Abstract Metallothionein (MT) is a metal binding protein of low molecular weight. It is involved in metal homeostasis, cell differentiation, proliferation, and detoxification of heavy metals. Neoplastic transformation in prostate cancer is attributed to elevated levels of metallothionein. We studied the expression of MT in prostate tissues. Immunohistochemistry (IHC) of 35 prostate cancer patients was performed to evaluate the expression of MT and then correlated with the expression profiles of epithelial TRAIL (Tumor necrosis factor related apoptosis inducing ligand), stromal TRAIL, decoy receptors (DcR1 and DcR2), death receptors (DR4 and DR5), nuclear factor κB (NF-κB), and FLICE inhibitory protein (FLIP). We also correlated expression patterns of these proteins using Pearson correlation with clinical histopathologic factors and determined their influence on overall survival of patients. Elevated levels of MT were observed in cancer tissues as compared to benign controls. Expression levels of epithelial TRAIL, DcR1, DcR2, DR4, DR5, NF-κB, and FLIP were also enhanced in cancer tissue samples. Age at diagnosis was significantly associated with stage (R= -0.467, p=0.046), MT (R= -0.419, p=0.012), DcR1 (R= 0.355, p=0.036) and sTRAIL (R= 0.553, p= 0.001). NF-κB significantly correlated with DR5 expression (R= 0.408, p = 0.015) in tumor tissues. Better survival was observed in patients with MT negative expression (p=0.467). Elevated levels of MT in prostate cancer patients and its positive correlation with FLIP and DcR1 depict its role as an antiapoptotic moiety. Further exploration of the role of MT in prostate cancer pathogenesis could help in establishing MT as a potential therapeutic target. Citation Format: Sobia Hamid, Mariam Anees. Role of metallothionein in the pathogenesis of prostate cancer [abstract]. In: Proceedings of the AACR Special Conference: Prostate Cancer: Advances in Basic, Translational, and Clinical Research; 2017 Dec 2-5; Orlando, Florida. Philadelphia (PA): AACR; Cancer Res 2018;78(16 Suppl):Abstract nr A022.
Efficacy and safety of mirikizumab ( <scp>LY</scp> 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase <scp>II</scp> study
Authors: K. Reich, P. Rich, C. Maari, R. Bissonnette, C. Leonardi, A. Menter, A. Igarashi, P. Klekotka, D. Patel, J. Li, J. Tuttle, M. Morgan‐Cox, E. Edson‐Heredia, S. Friedrich, K. Papp
Journal: British Journal of Dermatology (2019)

Inhibiting interleukin (IL)-23 in patients with psoriasis has demonstrated high levels of skin clearance.To investigate, in a phase II (AMAF; NCT02899988), multicentre, double-blind trial, the efficacy and safety of three doses of mirikizumab (LY3074828), a p19-directed IL-23 antibody, vs. placebo in patients with moderate-to-severe plaque psoriasis.Adult patients were randomized 1 : 1 : 1 : 1 to receive placebo (n = 52), mirikizumab 30 mg (n = 51), mirikizumab 100 mg (n = 51) or mirikizumab 300 mg (n = 51) subcutaneously at weeks 0 and 8. The primary objective was to evaluate the superiority of mirikizumab over placebo in achieving a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) response at week 16. Comparisons were done using logistic regression analysis with treatment, geographical region and previous biological therapy in the model. Missing data were imputed as nonresponses.Ninety-seven per cent of patients completed the first 16 weeks of the study. The primary end point was met for all mirikizumab dose groups vs. placebo, with PASI 90 response rates at week 16 of 0%, 29% (P = 0·009), 59% (P < 0·001) and 67% (P < 0·001) for patients receiving placebo, and mirikizumab 30 mg, 100 mg and 300 mg, respectively. There were two (1%) serious adverse events in mirikizumab-treated patients vs. one (2%) in a placebo-group patient.At week 16, 67% of patients treated with mirikizumab 300 mg at 8-week intervals achieved PASI 90. The percentage of patients reporting at least one treatment-emergent adverse event was similar among patients treated with placebo or mirikizumab.
The Realities of Liver Transplantation and Biliary Anastomosis—Heroes, Heroics, Heels, and Healing
Authors: Steven D. Colquhoun
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Treatment of Recurrent <i>Clostridium difficile</i> Infection
Authors: Stuart Johnson, Dale N. Gerding
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
Authors: Daniel A. C. Fisher, Cathrine A. Miner, Elizabeth K. Engle, Hengrui Hu, Taylor B. Collins, Amy Zhou, Maggie J. Allen, Olga N. Malkova, Stephen T. Oh
Journal: Leukemia (2019)
Abstract 15913: Optimization of Minimally-invasive Strategies for Lung-targeted, Vascular Delivery of MicroRNA Mimics in Rats
Authors: Kenny Schlosser, Mohamad Taha, Duncan Stewart
Journal: Circulation (2017)

Introduction: MicroRNAs (miRNA) have been implicated in the pathobiology of many diseases. Thus, there is increasing interest in the use of synthetic miRNA mimics or antagomirs as potential therapeutic agents in pulmonary vascular disease; however, the optimal delivery method to achieve high efficiency, selective lung targeting has not been determined. Objective: To assess the relative merits of different minimally-invasive strategies for lung-targeted administration of miRNA mimics in rats. Methods: A synthetic miRNA mimic, cel-miR-39-3p (0.5 nmol in 50 μL invivofectamine/PBS vehicle) was delivered to male SD rats (n=3 rats/method) using lung targeted strategies including intratracheal liquid instillation (IT-L), intratracheal non-ventilated aerosolization (Aeroneb) (IT-A), intranasal liquid instillation (IN-L) and intranasal aerosolization (IN-A). Intravenous (IV; via jugular vein), intraperitoneal (IP) and subcutaneous (SC) delivery served as controls. Relative levels of cel-miR-39 were quantified by R...
Abstract 15686: Cardiomyocyte SIRT1 Deficiency Alters Cardiac Substrate Metabolism and Sensitizes Myocardium to Ischemic Insults
Authors: Lin Wang, Chelsea Luckett, Courtney Cates, Thomas Rousselle, Xuan Li, Ji Li
Journal: Circulation (2017)

Introduction: A longevity gene, sirtuin 1 (SIRT1) is a conserved NAD+-dependent protein deacetylase. AMP-activated protein kinase (AMPK) is an energy sensor. AMPK and SIRT1 signaling pathways have ...
Dysregulated fatty acid metabolism in nasal polyp‐derived eosinophils from patients with chronic rhinosinusitis
Authors: Jun Miyata, Koichi Fukunaga, Yusuke Kawashima, Takashi Watanabe, Akina Saitoh, Tomomi Hirosaki, Yasutomo Araki, Toru Kikawada, Tomoko Betsuyaku, Osamu Ohara, Makoto Arita
Journal: Allergy (2019)

Abstract Background Eosinophils are multifunctional granulocytes capable of releasing various cytokines, chemokines, and lipid mediators. We previously reported dysregulated fatty acid metabolism in peripheral blood‐derived eosinophils from patients with severe asthma. However, functional characteristics of eosinophils present in allergic inflammatory tissues remain largely uncharacterized. Methods We established a method for isolating CD 69 hi CCR 3 low CXCR 4 ‐ siglec‐8 int eosinophils from nasal polyps of patients with eosinophilic rhinosinusitis ( NP ‐ EOS ). Multi‐omics analysis including lipidomics, proteomics, and transcriptomics was performed to analyze NP ‐ EOS as compared to peripheral blood‐derived eosinophils from healthy subjects ( PB ‐ EOS ). Results Lipidomic analysis revealed impaired synthesis of prostaglandins and 15‐lipoxygenase (15‐ LOX )‐derived mediators, and selective upregulation of leukotriene D 4 production. Furthermore, proteomics and transcriptomics revealed changes in the expression of specific enzymes ( GGT 5, DPEP 2, and 15‐ LOX ) responsible for dysregulated lipid metabolism. Ingenuity pathway analysis indicated the importance of type 2 cytokines and pattern recognition receptor pathways. Stimulation of PB ‐ EOS with eosinophil activators IL ‐5, GM ‐ CSF , and agonists of TLR 2 and NOD 2 mimicked the observed changes in lipid metabolism. Conclusion Inflammatory tissue‐derived eosinophils possess a specific phenotype with dysregulated fatty acid metabolism that may be targeted therapeutically to control eosinophilic inflammatory diseases.
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)
Authors: Nikolaus Jahn, Ekaterina Panina, Lars Bullinger, Anna Dolnik, Julia Herzig, Tamara J. Blätte, Axel Benner, Julia Krzykalla, Insa Gathmann, Richard A. Larson, Francesco Lo-Coco, Sergio Amadori, Thomas W Prior, Joseph M. Brandwein, Frederick R. Appelbaum, Bruno C. Medeiros, Martin S. Tallman, Eva Tiecke, Celine Pallaud, Gerhard Ehninger, Michael Heuser, Arnold Ganser, Richard M. Stone, Christian Thiede, Hartmut Döhner, Clara D. Bloomfield, Konstanze Döhner
Journal: Blood (2018)
Expression Status of Prohibitin Gene Predicts the Prognosis of Acute Myeloid Leukemia with Normal Cytogenetics
Authors: Myung Geun Shin, Jun Hyung Lee, Hye Ran Kim, Bo Ram Na, Young Eun Lee, Hyun Jung Choi, Soo Hyun Kim, Jong Hee Shin, Soon Pal Suh
Journal: Blood (2018)
Microporous polysaccharide multilayer coated BCP composite scaffolds with immobilised calcitriol promote osteoporotic bone regeneration both in vitro and in vivo
Authors: Qian Tang, Zhichao Hu, Haiming Jin, Gang Zheng, XingFang Yu, Gang Wu, Haixiao Liu, Zhenzhong Zhu, Huazi Xu, Changqing Zhang, Liyan Shen
Journal: Theranostics (2019)

Incorporating a biomimetic coating and integrating osteoinductive biomolecules into basic bone substitutes are two common strategies to improve osteogenic capabilities in bone tissue engineering. Currently, the underlying mechanism of osteoporosis (OP)-related deficiency of osteogenesis remains unclear, and few treatments target at OP-related bone regeneration. Herein, we describe a self-assembling polyelectrolyte multilayered (PEM) film coating with local immobilisation of calcitriol (Cal) in biphasic calcium phosphate (BCP) scaffolds to promote osteoporotic bone regeneration by targeting the calcium sensing receptor (CaSR).
Abstract P123: Comorbid Conditions May Explain Sex/ Race Disparities in Risk of Pulmonary Hypertension
Authors: H. Nicole Tran, Natalia Udaltsova, Stanton Siu, Jeanne Darbinian, Arthur L Klatsky
Journal: Circulation (2018)

Background: Pulmonary hypertension (PH) occurs as a rare idiopathic condition or more often with associated conditions (PH-COMORBID) including sleep apnea, COPD, and venous thromboembolism (VTE). Limited data suggest PH is commoner in women and Blacks, but less common in Asians. The sparseness of systematic epidemiologic studies of PH prompted our study of sex/race disparities and the role of 25 PH-COMORBIDs. Hypothesis: Sex/racial differences in PH are due substantially to PH-COMORBIDs. Methods: We studied PH and PH-COMORBID in 61,459 comprehensive health plan members with self-classified ethnicity on prior health exams. Subjects were 58% female, 42% male, 28% Black, 53% White, and 12% Asian. From 1996-2015, PH (ICD-9 code 416) was diagnosed at outpatient visits or hospitalization in 2,183 persons. We identified PH/COMORBIDs during the same study period. Cox models yielded hazard ratios (HR) and 95% confidence intervals (CI) for PH. The PH-CORMORBID conditions were studied individually as logistic regression endpoints and Cox model covariates with PH as endpoint. Results: In adjusted models, sex was unrelated to PH risk with male/female HR=1.05 (0.96-1.15). Increasing age, BMI and smoking were related to increased risk, while higher education was inversely related (table). Compared to Whites, Black women had increased risk, while Asians had similar risk. With p&lt;0.001 (statistically significant), Blacks had higher risk than Whites for 16 PH-COMORBIDs and were at decreased risk for none, while Asians were at higher risk than Whites for 10 PH-COMORBIDs and at decreased risk only for VTE. In the models with individual PH-COMORBID covariates, the greatest individual contributor to change in PH risk in Black women was hypertensive heart disease which decreased the HR from 1.31 (p&lt;0.001) to 1.15 (p=0.03). Several other PH-COMORBID covariates decreased the HR by approximately 0.10. Conclusions: Independent sex and race associations with PH are modest and substantially influenced by PH-COMORBID conditions.
Molecular Spectrum of CSF3R variants Correlate with Specific Myeloid Malignancies and Secondary Mutations
Authors: Vera Adema, Cassandra M. Hirsch, Bartlomiej Przychodzen, Yasunobu Nagata, Tomas Radivoyevitch, Thomas Laframboise, Amy C Graham, Louis Williams, Hassan Awada, Aziz Nazha, Hetty E. Carraway, Valeria Santini, Hrishikesh M Mehta, Francesc Sole, Mikkael A. Sekeres, Valeria Visconte, Rabi Hanna, Seth J. Corey, Jaroslaw P. Maciejewski
Journal: Blood (2018)
Achievement of High Concentration of Cyclosporine-a Is Associated with a Low Incidence of Acute Graft-Versus-Host Disease after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Graft
Authors: Nicolas Stocker, Remy Duléry, Clemence Mediavilla, Eolia Brissot, Giorgia Battipaglia, Simona Sestili, Annalisa Ruggeri, Razan Mohty, Mohamad Mohty, Florent Malard
Journal: Blood (2018)